Publications by authors named "Carlos Fernandez-Cid"
Objectives: The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyze treatment modalities, and determine impact on control of disease activity.
Methods: Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after reduction (6-12 months), and they were compared.
Background: In rheumatoid arthritis (RA), the activation of T and B cell clones specific for self-antigens leads to the chronic inflammation of the synovium. Here, we perform an in-depth quantitative analysis of the seven chains that comprise the adaptive immune receptor repertoire (AIRR) in RA.
Results: In comparison to controls, we show that RA patients have multiple and strong differences in the B cell receptor repertoire including reduced diversity as well as altered isotype, chain, and segment frequencies.
Introduction: One of the most important aims in the management of systemic lupus erythematosus (SLE) is to avoid or delay the accumulation of organ damage. The first five years after diagnosis are crucial for prognosis.
Areas Covered: This manuscript reviews available data on organ damage accrual in SLE and early therapeutic intervention as a possible strategy to prevent its long-term accrual.
Article Synopsis
- Rheumatoid arthritis (RA) is linked to changes in blood DNA methylation, and this study explores how these changes relate to the effectiveness of tumor necrosis factor inhibitor (TNFi) therapy.
- Researchers analyzed DNA methylation profiles in 62 RA patients before and after 12 weeks of TNFi treatment, identifying 139 biological functions influenced by the therapy that shifted toward healthy control patterns.
- The study found that the response to TNFi therapy is associated with specific methylation changes in immune cell types, indicating that the treatment helps restore normal blood methylation in RA patients.
To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.
View Article and Find Full Text PDFObjective: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as a first-line biologic drug over 1 year of treatment in a large series of patients with refractory uveitis due to Behçet's disease (BD).
Methods: We conducted an open-label multicenter study of IFX versus ADA for BD-related uveitis refractory to conventional nonbiologic treatment. IFX or ADA was chosen as the first-line biologic agent based on physician and patient agreement.
Purpose: Diagnosis of tuberculous uveitis (TBU) is often challenging and is usually made after excluding other causes of uveitis. We analysed the characteristics of TBU and variables associated with visual outcome.
Methods: A retrospective, observational analysis was performed in patients with presumptive TBU who were started on specific TB treatment between January 2006 and June 2016.
Article Synopsis
- The study evaluated the effectiveness of golimumab, an anti-TNF-α monoclonal antibody, for treating refractory uveitis associated with juvenile idiopathic arthritis (JIA).
- It included 7 patients, most of whom had previously been treated with multiple other biologic agents, and showed significant improvements in ocular symptoms and visual acuity after 6 months of golimumab therapy.
- The results suggest that golimumab could be a valuable option in managing difficult cases of JIA-related uveitis, although some patients experienced insufficient response and needed alternative treatments.
Objective: The aim of this study was to assess the efficacy of anti-TNF-α therapy in refractory uveitis due to Behçet's disease (BD).
Methods: We performed a multicentre study of 124 patients with BD uveitis refractory to conventional treatment including high-dose corticosteroids and at least one standard immunosuppressive agent. Patients were treated for at least 12 months with infliximab (IFX) (3-5 mg/kg at 0, 2 and 6 weeks and then every 4-8 weeks) or adalimumab (ADA) (usually 40 mg every 2 weeks).
Objective: To evaluate adalimumab therapy in refractory uveitis.
Design: Prospective case series.
Participants: A total of 131 patients with refractory uveitis and intolerance or failure to respond to prednisone and at least 1 other systemic immunosuppressive drug participated.